that we identified is insulin-like growth factor (IGF)-binding protein (IGFBP)-related protein-1 (IGFBP-rP1).
IGF signaling pathways play important roles in regulating proliferation, differentiation, and apoptosis (3, 12) . The IGF system consists of ligands (IGF-I and IGF-II), its receptors (IGF-IR and IGF-IIR), and IGFBPs. IGFBPs regulate IGF signals positively and negatively. The IGFBP superfamily includes 6 members with high affinity for IGF-I and IGF-II (IGFBP-1-IGFBP-6) and 10 related proteins (IGFBP-rP1-IGFBP-rP10) with low affinity for these ligands. IGFBP-rPs share the conserved NH 2 -terminal domain with other IGFBPs. The gene encoding IGFBP-rP1, IGFBP7, binds to IGFs with an affinity 100-fold lower than that of the conventional IGFBPs (20) . By contrast, IGFBP-rP1 binds insulin with an affinity 500-fold higher than that of other IGFBPs and, thereby, inhibits insulin signaling (36) . IGFBP-rP1 also has IGF/insulinindependent effects: IGFBP-rP1 can slow tumor growth (4, 14) and induce cellular senescence in tumor cells (28, 29, 34) , and it may also contribute to cell differentiation (21) . However, the function of IGFBP-rP1 is not well known.
In the present report, we describe the results of proteomic profiling showing that 44 proteins are present in podocyteconditioned culture medium, including IGFBP-rP1. We further show that the IGFBP-rP1 is expressed in injured podocytes in a mouse model of human immunodeficiency virus-associated nephropathy (HIVAN).
MATERIALS AND METHODS

Cell Culture
We used a conditionally immortalized human podocyte cell line that has been previously described (25) . Briefly, podocytes were grown on collagen type I-coated flasks under permissive conditions at 33°C or under nonpermissive conditions at 37°C. For proteomic analysis, differentiated podocyte cell layers (see Supplemental Fig. S1B in Supplemental Material for this article, which is available online at the Journal website) were washed five times with serum-free RPMI 1640 medium to remove residual proteins from the serumsupplemented culture medium. After the final wash, the cells were cultured in serum-free, phenol red-free RPMI 1640 medium supplemented with insulin (10 g/ml), selenium (5 ng/ml), and transferrin (5.5 g/ml; Invitrogen, Carlsbad, CA) for 48 h (see Supplemental Fig.  S1A ). For the stimulation study, differentiated podocytes were treated with transforming growth factor (TGF)-␤1 (10 ng/ml; R & D Systems, Minneapolis, MN) for 48 h under the serum-free condition. Human mesangial cells (gift of Dr. Javier Lucio-Cavanza, Madrid, Spain) were cultured in RPMI 1640 medium supplemented with 10% FBS. Two breast adenocarcinoma cell lines, Hs578T (gift of Dr. Christine Horak, National Cancer Institute) and MCF7 (gift of Dr. Vi Luan Ha, National Cancer Institute), served as positive and negative controls for IGFBP-rP1 expression and were cultured in DMEM supplemented with 10% FBS.
Assays
Sample preparation and proteomic analysis. Conditioned medium was collected and centrifuged at 2,000 g for 15 min to separate cell debris. The supernatant was concentrated using Macrosep centrifugal devices (Pall Life Science, Ann Arbor, MI). The protein concentration was determined by the bicinchoninic acid protein assay (Pierce, Rockford, IL). We used a combination of one-dimensional gel separation and a liquid chromatography-tandem mass spectrometry (LC-MS/MS) approach (5, 6) to analyze the conditioned medium. Briefly, conditioned medium was separated with SDS-PAGE. The nonreduced 100 g of total proteins from conditioned medium were heated at 70°C for 10 min in SDS-Laemmli buffer and separated on a 10% Bis-Tris gel (Invitrogen). The gel was stained with colloidal Coomassie stain (Invitrogen; see Supplemental Fig. S1C ) and sliced into 20 equal parts. After digestion with trypsin (Promega, Madison, WI) and lysyl endopeptidase (Roche, Indianapolis, IN), peptides were extracted and analyzed with LC-MS/MS (Fourier transform ion cyclotron resonance mass spectrometry, Thermo Finnigan, Waltham, MA). For protein identification, peptides were searched against the NCBInr database limited to human using the MASCOT search engine (Matrix Science, Boston, MA). False discovery rates (FDR) were determined by using a decoy database. Protein FDR was set to Ͻ3% (for additional information, see Supplemental Data 1).
RNA preparation and RT-PCR. Total RNA was isolated from cultured podocytes using the RNeasy Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's protocol. Single-strand cDNA was prepared from 1 g of total RNA with random primers and avian myeloblastosis virus reverse transcriptase (Roche) by incubation of 20 l of the mixture at 42°C for 1 h. The cDNA was subjected to PCR using the gene-specific oligonucleotide primers. The sequences of primers were as follows: ATCTGGAATGTCACTGGTGCCC (forward) and TGATGCTGAAGCCTGTCCTTGG (reverse) for human IGFBP-rP1 (IGFBP7, product size ϭ 276 bp) and CCGGGAAACT-GTGGCGTGAT (forward) and GAAGGCCATGCCAGTGAGCT (reverse) for human GAPDH (product size ϭ 476 bp).
We amplified messenger RNA products using the Taq PCR Master Mix Kit (Qiagen) following the manufacturer's protocol. The reaction consisted of 25 cycles at 94°C for 30 s, 56°C for 30 s, and 72°C for 1 min. Bands were detected and analyzed with ChemiImager 4400 (Alpha Innotech, San Leandro, CA).
Murine model of HIVAN. Previously established bitransgenic mice (podocin/rtTA ϫ tet-O/Vpr) express the Vpr gene selectively in podocytes after administration of doxycycline (Sigma-Aldrich, St. Louis, MO; see Supplemental Fig. S2A ). Mice at 6 -14 wk of age were uninephrectomized 1 wk before the administration of doxycycline to accelerate podocyte injury. Drinking water containing doxycyline (2 mg/ml) was provided over 4 or 8 wk to induce Vpr gene expression. As previously reported, uninephrectomized Vpr-transgenic mice showed heavy albuminuria, glomerulosclerosis, and tubulointerstitital changes at 4 -8 wk after administration of doxycycline (11) (see Supplemental Fig. S2 , B and C). We used FVB/N mice as normal wild-type. Mice were cared for under protocols approved by the National Institutes of Health (NIH) Animal Care and Use Committee, and the protocols adhered to the NIH Guide for the Care and Use of Laboratory Animals.
Immunofluorescence studies in vitro and in vivo. Cultured cells were fixed in cold methanol, and frozen kidney tissue sections were fixed in cold acetone for 5 min or 4% paraformaldehyde for 10 min. Nonspecific binding was blocked using blocking buffer for 1 h at room temperature. The slides were incubated with goat anti-human or rabbit anti-mouse IGFBP7 (IGFBP-rP1) antibody (Santa Cruz Biotechnology, Santa Cruz, CA), guinea pig anti-nephrin antibody, and mouse anti-synaptopodin antibody (Progen, Heidelberg, Germany) at 4°C overnight and then with Alexa 488-or Alexa 568-conjugated secondary antibody (Invitrogen) for 1 h. After several washes with PBS, slides were embedded in mounting reagent (Invitrogen). To demonstrate specificity of the anti-human IGFBP7 antibody, blocking peptide (Santa Cruz Biotechnology) was used. Images were captured using a fluorescence microscope (Leica Microsystems, Wetzlar, Germany) and were digitally processed using Adobe Photoshop CS2.
Western blot analysis. Total protein (30 g) from samples was heated at 70°C for 10 min in SDS-Laemmli buffer, separated on a 4 -12% gradient Bis-Tris gel (Invitrogen) under reduced conditions, and transferred onto a nitrocellulose membrane (Pierce). The membrane was blocked with 5% nonfat milk dissolved in PBS with 0.05% Tween 20 and probed with goat anti-human IGFBP7, rabbit anti-plasminogen activator inhibitor-1 (PAI-1; Santa Cruz Biotechnology), or mouse anti-metalloproteinase inhibitor 1 (TIMP-1; 7-6C1, EMD Biosciences, San Diego, CA) as primary antibody at 4°C overnight. The membrane was then incubated with the diluted horseradish peroxidase-conjugated secondary antibody (Pierce) for 1 h at room temperature. After several washing steps in Tween-PBS, a chemoluminescent substrate (Pierce) was added to the membrane, which was then exposed to Biomax film (Kodak, Rochester, NY). Densitometric analysis was performed with ImageJ software (version 1.33u, NIH, Bethesda, MD).
Immunohistochemistry of tissue. Zinc-formalin-fixed, paraffin-embedded kidney tissues were sectioned at 4 m and deparaffinized. Antigen unmasking was accomplished by heating slides in a microwave oven in citrate buffer (pH 6.0). Endogenous peroxidase was quenched by periodic acid (Nichirei, Tokyo, Japan). Tissues were blocked by 10% goat serum. After they were rinsed briefly in PBS, the slides were incubated overnight at 4°C with rabbit anti-mouse IGFBP7 primary antibody (Santa Cruz Biotechnology). After several washes in PBS, the slides were incubated with biotinylated secondary antibody and streptavidin-peroxidase reagent (Vector Laboratories, Burlingame, CA) according to the manufacturer's protocol. The peroxidase substrate was diaminobenzidine, and the counterstain was methyl green solution (Wako Pure Chemical Industries, Osaka, Japan). To analyze percentage of IGFBP-rP1-positive-staining area in glomeruli and tubules, we measured positive staining within the glomerular area, total intraglomerular area, and tubular area digitally using ImageJ software for quantification. We assessed a total of 50 glomeruli for each group (10 glomeruli in each of 5 mice) and a total 25 tubular areas per group (5 tubular areas in each of 5 mice).
Lactate dehydrogenase assay. Human podocytes were cultured with fresh medium with or without FBS, and the conditioned medium was collected after 8, 24, and 48 h. Lactate dehydrogenase (LDH) assay was performed with LDH-Cytotoxity Assay Kit II (BioVision, Mountain View, CA) according to the manufacturer's instructions. The background amount of LDH in fresh serum-containing medium was subtracted from all samples. Results are expressed as fraction of positive supplied by the manufacturer.
Statistics
Statistical analysis was performed using PRISM 4.0c (GraphPad Software, San Diego, CA). Values are means Ϯ SE. Data were analyzed by unpaired t-test, and P Ͻ 0.05 was considered to be statistically significant.
RESULTS
Using one-dimensional electrophoresis followed by LC-MS/ MS, we detected and identified 111 unique protein candidates (see Supplemental Table S1 ) in the conditioned medium of cultured human podocytes at an FDR Ͻ3%. Of these, 43 proteins were described as secreted proteins in the UniProt database or are predicted to have signal peptides as shown in 
Yes
Yes Continued lular proteins lacking signal peptides and proteins that likely represent contaminants from the culture system: albumin and fetuin, which are present in FBS; transferrin, which is added to culture medium as a supplement; collagen 1, which is used to coat the surface of culture flasks and dishes; keratin, which is likely derived from human skin; and trypsin, which is from the digestion procedure. (All identified proteins are listed in Supplemental Table S1 .)
The proteins that we have identified as possible components of the secretory podocyte proteome of cultured podocytes represent several protein classes. The most numerous class of proteins consisted of extracellular matrix-and cell adhesionrelated proteins, including annexin A 2 , collagen XVIII ␣1 chain, fibronectin, fibrillin-1, thrombospondin-1, agrin, versican core protein, lysyl oxidase-like protein 2, basement membrane-specific heparan sulfate proteoglycan core protein, secreted protein acidic and rich in cysteine (SPARC), osteopontin, testican-1, lumican, calsyntenin-1, lysosome-associated membrane glycoprotein-2, and desmocolin-3. Other proteins that are represented include 1) proteases and protease regulators, including carboxypeptidase A 4 , carboxypeptidase E, PAI-1, TIMP-1 and -2, urokinase-type plasminogen activator, and peptidyl-prolyl cis-trans isomerase; 2) binding proteins, including ␣-2 HS glycoprotein, IGFBP-rP1, IGFBP-5, and galectin-1; 3) cytokines and growth factors, including interleukin-6, follistatin-related protein 1, inhibin-␤ chain A; and 4) chemokines, including CXCL1. Other proteins included complement C3, protein disulfide isomerase, protein disulfide isomerase A3, coiled-coil domain-containing protein, syndecan-4, reticulocalbin-1, Dickkopf-related protein-3, lipocalin, stanniocalcin-2, and (at 5% FDR) glypican-1. While we chose IGFBPrP1 for primary validation studies, we confirmed the presence of two other proteins, TIMP-1 and PAI-1, in conditioned medium by Western blot analysis (Fig. 1D) .
We considered whether serum-free culture conditions might be associated with cell injury and cause a release of intracellular proteins; we therefore measured the release of LDH, an intracellular protein (see Supplemental Fig. S3 ). The amount of LDH released was modestly elevated after 8 h (1.5-fold) and 48 h (1.9-fold) of serum-free culture compared with culture in serum-containing medium. We interpret these results to suggest that cytotoxicity was mild and unlikely to have caused a major distortion in the profile of proteins in conditioned medium, although a subtle role for cell death is not excluded.
IGFBP-rP1 had the highest probability-based scores among podocyte secretory proteome, excluding likely contaminants and products that were reported previously. We focused on this protein for validation and further study as a novel podocyte secretory protein. 1) Using RT-PCR, we examined mRNA expression of IGFBP-rP1 in a conditionally immortalized human cultured podocyte cell line and found that cultured human podocytes expressed abundant IGFBP-rP1 mRNA (Fig. 1A) . By contrast, mesangial cells expressed IGFBP-rP1 at much lower levels. 2) Using immunofluorescent staining, we showed that IGFBP-rP1 protein localized to the cytoplasm of cultured podocytes (data not shown). 3) Using Western blotting, we examined the IGFBP-rP1 protein expression in cell lysates and conditioned medium (Fig. 1, B and C) . We detected IGFBPrP1 protein as a ϳ31-kDa band from podocyte cell lysate (Fig.  1B) and conditioned medium (Fig. 1C) cultured at 37°C. IGFBP-rP1 was not detected in mesangial cell lysate (Fig. 1B) . Since TGF-␤ is an important mediator of podocyte damage (26), we analyzed the influence of TGF-␤1 (10 ng/ml) on IGFBPrP1 expression by human cultured podocytes. TGF-␤1 increased IGFBP-rP1 protein expression in cell lysates and conditioned medium by 2.2-and 6-fold, respectively (Fig. 1, B and C) .
We next examined IGFBP-rP1 protein expression in vivo. In normal FVB/N mouse kidney stained using the immunoperoxidase technique, we detected IGFBP-rP1 in tubular epithelial cells and glomerular parietal epithelial cells but no convincing staining in intraglomerular cells, including podocytes ( Fig. 2A) . By contrast, using the arguably more sensitive immunofluoresence technique, we detected weak staining of IGFBP-rP1 protein within glomeruli. It may be colocalized with the podocyte marker synaptopodin partially, but it was difficult to confirm the colocalization because of weak signal (Fig. 3A,  top) .
To examine whether IGFBP-rP1 expression is changed in glomerular disease, we analyzed IGFBP-rP1 expression in the uninephrectomized Vpr-transgenic (TG) mouse, which is a mouse model of HIVAN representing podocyte injury and dysregulation (collapsing glomerulopathy) and progressive focal segmental glomerulosclerosis. Using immunoperoxidase staining, we detected IGFBP-rP1 protein not only in tubular epithelial cells, but also intraglomerular lesions. We detected strong staining at the outside of glomerular tufts and pseudocrescentic lesions (Fig. 2, B, C, F, and G) . To evaluate whether IGFBP-rP1 is increased in TG mice, we analyzed IGFBP-rP1-positive staining in glomeruli. The IGFBP-rP1-positive area in the glomerulus was increased in TG mice compared with wild-type (WT) control mice: 21.2 Ϯ 0.9 vs. 4.7 Ϯ 0.3% (P Ͻ 0.0001; Fig. 2H ). Using the immunofluorescence technique, we detected decreased synaptopodin staining in glomeruli of TG mice. However, IGFBP-rP1 was partially coexpressed with synaptopodin in a small fraction of glomeruli, where synaptopodin staining remained (Fig. 3A, bottom) . IGFBP-rP1 was also expressed in dysregulated podocytes, where it colocalized with the injury marker desmin (Fig. 3B) . By contrast, there was no significant difference in IGFBP-rP1 staining between TG and WT mice in the tubular area: 8.3 Ϯ 0.7 and 7.5 Ϯ 0.5%, respectively (P ϭ 0.38).
We analyzed IGFBP-rP1 expression in normal mouse developing kidney. In embryonic day 18.5 fetal kidney, IGFBPrP1 expression appeared at the periphery of the kidney (Fig. 4A) . In postnatal day 1 kidney, IGFBP-rP1 expression was seen in glomerular and tubular lesions. In the glomerulus, IGFBP-rP1 was expressed in column-like immature podocytes and parietal epithelial cells (Fig. 4B) . In postnatal day 7 kidney, IGFBP-rP1 expression was dominant in the tubular lesion; however, the expression in glomeruli decreased compared with that in postnatal day 1 kidney (Fig. 4C) . IGFBP-rP1 was not expressed in the glomerulus at the comma-shaped stage (Fig. 4E) . IGFBP-rP1 expression was detected from the S-shaped body stage (Fig. 4F) and was most increased at the capillary-loop stage (Fig. 4G) . IGFBP-rP1 expression decreased in the maturing glomerulus compared with the capillary-loop stage (Fig. 4H) . , and MCF7 breast carcinoma cells (negative control) was reverse transcribed and subjected to PCR using primer sets for human IGFBP-rP1 (276 bp) and human GAPDH (476 bp). B and C: Western blot analysis was performed to detect IGFBP-rP1 in cell lysates, and conditioned medium was obtained from human podocytes cultured at 37°C and at 37°C in the presence of TGF-␤1 (10 ng/ml) for 48 h. B: IGFBP-rP1 was detected in cell lysate from human podocytes (Podo) at 37°C, and TGF-␤1 increased expression 2.2-fold compared with control at 37°C. C: IGFBP-rP1 was detected in conditioned medium from human podocytes at 37°C, and TGF-␤1 further increased expression 6-fold compared with that at 37°C. IGFBP-rP1 was not detected in medium alone and in conditioned medium from podocytes cultured at 33°C. D: Western blots showing tissue inhibitor of metalloproteinase-1 (TIMP-1) and plasminogen activator inhibitor-1 (PAI-1) proteins in conditioned medium collected from human podocytes cultured at 37°C. Recombinant human TIMP-1 protein and human umbilical vein endothelial cell protein lysate containing PAI-1 were used as positive controls.
DISCUSSION
Proteomic profiling of podocyte cultured medium revealed 44 secreted proteins. Transferrin, serum albumin, and collagen ␣ 1 chain I were likely contaminants from the culture system, and keratin was likely a contaminant from skin and hair. Fibronectin (19) , thrombospondin-1 (15), SPARC (8), vesican (2), osteopontin (9), protein disulfide isomerase (31), IL-6 (35), glypican-1 (2), and urokinase plasminogen activator receptor/ urokinase-type plasminogen activator (33) were previously known to be podocyte products. The remaining proteins have not been previously associated with podocytes. It is possible that some proteins that are known to be present in plasma, such as PAI-1, could also represent contaminants from the cell culture system. There were also 67 proteins that lacked signal peptides and may represent intracellular proteins, either physiologically released by various mechanisms or released from injured cells. A potential pitfall in analysis of the secretory proteome is contamination from serum proteins. We incubated the cell line in the serum-free condition after several washes to reduce serum contamination. It may be unsuitable for the cell line and affect the expression profiles, but our result included nine proteins that have been reported as podocyte products. Although further validation studies are required to clarify the source of each protein identified in this proteomic analysis, this information may be useful to expand our understanding of podocyte biology or to discover novel podocyte biomarkers.
To validate our approach to identifying podocyte proteins, we focused on IGFBP-rP1 for further study. Using RT-PCR, we demonstrated that cultured podocytes express IGFBP-rP1 mRNA, and using Western blotting, we demonstrated that the protein is present in cell lysates and conditioned medium from cultured podocytes. TGF-␤1 has been shown to regulate IGFBP-rP1 expression in primary and immortalized normal human prostate epithelial cells (13, 17) , and we found a similar response in conditionally immortalized human podocytes. Since TGF-␤ induces podocyte damage and leads to apoptosis (26), we hypothesize that injured podocytes in glomerular diseases may express IGFBP-rP1. It remains to be determined whether and how IGFBP-rP1 modulates TGF-␤ signaling or acts as a signaling mediator, similar to the IGFBP family member IGFBP3 (22) .
Our study showed that IGFBP-rP1 is expressed by tubular epithelial cells dominantly and glomerular parietal epithelial cells in normal mouse kidney. Because IGFBP-rP1 was expressed at lower levels by intraglomerular cells, it was difficult to confirm, by immunostaining techniques, whether podocytes expressed IGFBP-rP1 in normal mouse kidney. We further analyzed IGFBP-rP1 expression in the Vpr-transgenic mouse. As previously shown, conditional Vpr gene expression leads to podocyte damage, dysregulation, proteinuria, and collapsing glomerulopathy with glomerulosclerosis. We demonstrated that the IGFBP-rP1 protein was expressed in podocytes of the Vpr-transgenic mouse, as shown by double immunostaining. A recent report showed that oncogenic activation in human fibroblasts and melanocytes leads to synthesis of IGFBP-rP1 and induces senescence and apoptosis in an autocrine/paracrine manner (32) . The Vpr-transgenic mouse represents podocyte dysregulation and apoptosis after doxycycline administration (11) . It is possible that podocyte dysregulation by the Vpr gene may lead to IGFBP-rP1 secretion. Some stress leading to podocyte injury may contribute to IGFBP-rP1 expression in focal segmental glomerulosclerosis. IGFBP-rP1 expression also increased in developing glomeruli. IGFBP-rP1 appeared from the S-shaped stage, increased most at the capillary-loop stage, and decreased in maturing glomeruli. Since synaptopodin, known as a podocyte differentiation marker, is expressed from the S-shaped stage (1), IGFBPrP1 expression may be related to the differentiation of podocytes. Our findings indicate that IGFBP-rP1 expression increased in podocytes during differentiation or dedifferentiation. Since IGFBP-rP1 regulates cell growth in cancer cells (4, 14, 28, 34) , it is possible that IGFBP-rP1 may be associated with cell cycle regulation. It remains to be determined whether IGFBP-rP1 acts as a survival factor, phenotype stabilizing factor, or mediator of injury.
We showed that IGFBP-rP1 is expressed in mature differentiated podocytes in vitro, while IGFBP-rP1 is expressed in injured podocytes in tissue. It is possible that the difference of the phenotype between in vitro and in vivo may be related to the expression level. On the one hand, using the immunoperoxidase staining technique, Degeorges et al. (7) and LopezBermejo et al. (18) reported that IGFBP-rP1 is expressed in the tubular epithelium and is absent from glomeruli in normal human kidney. On the other hand, He et al. (10) demonstrated IGFBP-rP1 expression in glomeruli of fetal and adult mouse kidney, and, using the in situ hybridization technique, Fujinaka et al. showed IGFBP-rP1 expression in normal human kidney (unpublished data). Another possibility is that culture condition may affect IGFBP-rP1 expression in human cultured podocytes during 2 wk of cultivation. Since TGF-␤1 increased IGFBPrP1 expression, some growth factors in serum may influence IGFBP-rP1 expression of cultured human podocytes. Finally, it is possible that interaction among podocytes, endothelial cells, and mesangial cells may affect IGFBP-rP1 expression in the tissue.
In conclusion, we have analyzed proteins from podocyteconditioned medium and identified 44 proteins that likely represent secreted proteins. Of these, 9 proteins were previously reported to be podocyte products and 35 proteins are candidate podocyte products. We confirmed that IGFBP-rP1 is produced by cultured podocytes and found that it is upregulated by TGF-␤1. Furthermore, we showed that IGFBP-rP1 was expressed in dysregulated podocytes in a mouse HIVAN model and in immature podocytes in the developing kidney. Although further studies are required to determine the physiological and pathophysiological roles of IGFBP-rP1 in podocyte biology, our finding suggests that IGFBP-rP1 may contribute to the podocyte response to injury.
